Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer

被引：0
|
作者：
Dan Lu
Chunze Li
Matthew Riggs
Daniel Polhamus
Jonathan French
Priya Agarwal
Shang-Chiung Chen
Shweta Vadhavkar
Monika Patre
Alexander Strasak
Angelica Quartino
Jin Yan Jin
Sandhya Girish
机构：
[1] Genentech,Department of Clinical Pharmacology
[2] Inc.,undefined
[3] Metrum Research Group,undefined
[4] F. Hoffmann-La Roche Ltd.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Trastuzumab emtansine (T-DM1); HER2; Pharmacokinetics; Previously untreated metastatic breast cancer; MARIANNE;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：175 / 185
页数：10
相关论文
共 50 条
  • [31] HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
    Hitomi Sakai
    Junji Tsurutani
    Tsutomu Iwasa
    Yoshifumi Komoike
    Kazuko Sakai
    Kazuto Nishio
    Kazuhiko Nakagawa
    Breast Cancer, 2018, 25 : 605 - 613
  • [32] HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
    Sakai, Hitomi
    Tsurutani, Junji
    Iwasa, Tsutomu
    Komoike, Yoshifumi
    Sakai, Kazuko
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    BREAST CANCER, 2018, 25 (05) : 605 - 613
  • [33] Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
    Gebhart, G.
    Lamberts, L. E.
    Wimana, Z.
    Garcia, C.
    Emonts, P.
    Ameye, L.
    Stroobants, S.
    Huizing, M.
    Aftimos, P.
    Tol, J.
    Oyen, W. J. G.
    Vugts, D. J.
    Hoekstra, O. S.
    Schroder, C. P.
    van Oordt, C. W. Menke-van der Houven
    Guiot, T.
    Brouwers, A. H.
    Awada, A.
    de Vries, E. G. E.
    Flamen, P.
    ANNALS OF ONCOLOGY, 2016, 27 (04) : 619 - 624
  • [34] T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
    Omarini, Claudia
    Piacentini, Federico
    Sperduti, Isabella
    Cerma, Krisida
    Barbolini, Monica
    Canino, Fabio
    Nasso, Cecilia
    Isca, Christel
    Caggia, Federica
    Dominici, Massimo
    Moscetti, Luca
    BMC CANCER, 2022, 22 (01)
  • [35] A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer
    Paridaens, R.
    Rixe, O.
    Pinel, M. C.
    Wildiers, H.
    Zorza, G.
    Ferre, P.
    Roche, H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 503 - 511
  • [36] A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer
    R. Paridaens
    O. Rixe
    M. C. Pinel
    H. Wildiers
    G. Zorza
    P. Ferré
    H. Roche
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 503 - 511
  • [37] Pertuzumab in HER2-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) : 1709 - 1716
  • [38] Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer
    Yamamoto, Harukaze
    Ando, Masashi
    Aogi, Kenjiro
    Iwata, Hiroji
    Tamura, Kenji
    Yonemori, Kan
    Shimizu, Chikako
    Hara, Fumikata
    Takabatake, Daisuke
    Hattori, Masaya
    Asakawa, Takashi
    Fujiwara, Yasuhiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (01) : 12 - 18
  • [39] Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
    Sandhya Girish
    Manish Gupta
    Bei Wang
    Dan Lu
    Ian E. Krop
    Charles L. Vogel
    Howard A. Burris III
    Patricia M. LoRusso
    Joo-Hee Yi
    Ola Saad
    Barbara Tong
    Yu-Waye Chu
    Scott Holden
    Amita Joshi
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1229 - 1240
  • [40] Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
    Al Rabadi, Luai S.
    Cook, Madeline M.
    Kaempf, Andy J.
    Saraceni, Megan M.
    Savin, Michael A.
    Mitri, Zahi, I
    BMC CANCER, 2021, 21 (01)
12345